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In this study, we investigated whether mouse alpha feto-
protein (mAFP), the shared self/tumor antigen of hepato-
cellular carcinoma (HCC), could be rationally engineered
to create effective vaccine to break tolerance and potently
activate CD8 T cells to prevent clinically-relevant carcino-
gen-induced autochthonous HCC. We found that the
computer-guided epitope-optimization created optimized
opt-mAFP and that immunization with lentivector (lv)
expressing opt-mAFP, but not wt-mAFP, potently acti-
vated CD8 cells specific for three novel H-2b restricted
CD8 epitopes, which cross-recognized wt-mAFP epitopes
naturally processed and presented by wt-mAFP+ tumor
cells. Immunization with opt-mAFP-lv, but not wt-mAFP-
lv, completely protected mice from wt-mAFP+ tumor
challenge and effectively prevented carcinogen-induced
autochthonous HCC. Prime-boost with opt-mAFP-lv and
vaccinia vector opt-mAFP-vv significantly increased the
wt-mAFP-specific CD8 T cells that were highly responsive
to emerging HCC tumor cells in the liver, enhancing
prevention of autochthonous HCC. Our data demonstrate
that epitope-optimization creates immunogenic opt-mAFP
that is able to break tolerance and activate potent CD8
responses, which can cross-recognize wt-mAFP peptides,
but also recognize and kill mAFP+ tumor cells. Our study
provides a practical roadmap to develop effective human
vaccines that should have a better chance of success than
the current human HCC vaccines based on native wt-AFP.
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